Latest News and Press Releases

Paris, May 21, 2025 (GLOBE NEWSWIRE) -- — Trwały efekt terapeutyczny z istotnie niższym współczynnikiem niepowodzeń leczenia zmiany docelowej (TLF) – 2,7% wobec 7,2% (p=0,030) dla DynamX® w...

Paris, May 21, 2025 (GLOBE NEWSWIRE) -- —Durata sostenuta dell’efficacia del trattamento con tassi di TLF significativamente inferiori (2,7% vs. 7,2%, p=0,030) con DynamX® rispetto al DES— —Tasso...

Paris, May 21, 2025 (GLOBE NEWSWIRE) -- —Durabilidad sostenida del efecto del tratamiento y tasas de fracaso de la lesión objetivo significativamente menores (2,7 % frente a 7,2 %, p=0,030) con...

Paris, 21 mai 2025 (GLOBE NEWSWIRE) -- —Un effet thérapeutique durable avec des taux de TLF significativement inférieurs (2,7 % contre 7,2 %, p = 0,030) avec DynamX® par rapport au SEM— —Taux de...

Paris, May 21, 2025 (GLOBE NEWSWIRE) -- – Anhaltende Dauerhaftigkeit des Behandlungseffekts bei signifikant niedrigeren TLF-Raten (2,7 % vs. 7,2 %, p = 0,030) bei DynamX® im Vergleich zu DES – –...

Paris, May 21, 2025 (GLOBE NEWSWIRE) -- —Sustained durability of treatment effect with significantly lower TLF rates (2.7% versus 7.2%, p=0.030) with DynamX® compared to DES— —Significantly lower...

First cases completed by Dr. Tamil Selvan Muthusamy, MD, and Dr. Rosli Mohd Ali, MD, and transmitted live at TCTAP Congress in Seoul, Korea. Novel IVL technology designed to deliver calcium...

Novel IVL technology designed to deliver calcium fragmentation for treatment of moderate to severely calcified coronary artery lesions without requiring an energy source. IVL technology expands...

I dati del sistema LithiX HC-IVL di Elixir Medical dimostrano una sicurezza e un'efficacia durature a sei mesi — I dati dello studio PINNACLE I di Elixir per la frammentazione del calcio nelle...

Elixir Medical’s LithiX HC-IVL System Data Demonstrate Sustained Safety and Efficacy at Six Months —Data from Elixir’s PINNACLE I trial for calcium fragmentation in calcified coronary artery lesions...